ZBRA drops 14% post-earnings as options traders collect on defensive bets

Zebra Technologies reported earnings on November 3 and the market's verdict was swift: the stock fell 8.8% on the day and is now down 13.7% over the past week to $329.50, underperforming the median move of minus 7.5% among its closest peers.

The options market had priced in trouble. The put/call ratio closed at 1.79 on November 3, against a 20-day mean of 1.46 and more than two standard deviations above that average. That elevated reading, which had been building since late October when the PCR jumped from around 1.40 to above 1.77, reflected genuine demand for downside protection rather than speculative noise. The 52-week PCR range runs from 0.33 to 2.27, and the recent cluster of readings above 1.78 put the market firmly in the defensive portion of that band. Those puts paid off. Cost to borrow, which had spiked 84% over the prior month to 0.66% ahead of the print, has since eased back to 0.47%, consistent with the event-driven repricing that was flagged as the more likely explanation for the borrowing cost move. Availability remains extraordinarily loose, with roughly 9,999 shares available for every one currently lent out, so the borrow market imposes no friction on anyone rebuilding a short position.

Short interest itself is a secondary story here. Positions fell 1.5% over the past week to 2.8% of the free float, continuing a trend that has now taken shorts down more than 21% over the past month. At that level, short interest is not the driver of this week's move. The covering that accelerated into earnings has left the register lightly positioned, and the post-earnings selloff appears to be driven by long-side disappointment rather than any squeeze unwind.

Analyst reaction has been mixed in tone but mostly constructive on direction. The two most recent moves, both filed on November 4, tell slightly different stories. Morgan Stanley raised its target from $360 to $380 while keeping an Equal-Weight rating, an acknowledgement of some recovery but not a ringing endorsement at current prices. BNP Paribas trimmed its target by $5 to $455 while maintaining Outperform, a marginal adjustment that leaves a large implied premium to where the stock is trading. The mean price target across the Street is $417, roughly 27% above the current price. That gap reflects genuine disagreement rather than stale data: bulls point to Zebra's mission-critical automation portfolio across logistics and retail, the Elo Touch acquisition, and the company's earlier guidance raise citing $1.495 billion in sales and 23.2% EBITDA margins. Bears focus on short-cycle deceleration in those same end markets and the risk that the top three distributors, which account for 50% of sales, pull back on orders. The forward earnings yield factor ranks in the 69th percentile, and the 12-month forward EPS growth score sits in the 98th percentile, suggesting the market was paying for growth that the Q3 print may not have fully delivered.

The one genuinely positive data point from the company's own filings is the buyback programme. Zebra spent $300 million on repurchases in Q2, up 140% on the same quarter last year and the largest Q2 buyback figure in three years. That is a meaningful capital return signal for a company with a market cap now closer to $15.6 billion after this week's decline. Boston Partners added 415,000 shares in the September quarter, bringing its reported stake to 5.5% of shares outstanding. BlackRock added 46,000 shares over the same period. Neither move looks like a defensive trim.

The only prior earnings reaction available in the data is from August 4, when Zebra's stock rose 26.5% on the day and 31.3% over the five days following the Q2 print, the report that showed 14.3% sales growth and prompted target upgrades across the Street. That sets an unusually high reference point. The Q3 reaction, a loss of 8.8% on the day, represents a stark reversal in market sentiment, and what happened between those two prints, specifically whether the Q3 guidance or revenue trend disappointed against the Q2 bar, is now the central question for investors rebuilding their views. The next earnings date is February 16, 2027, giving 104 days for the data and the debate to settle.